<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681095</url>
  </required_header>
  <id_info>
    <org_study_id>HIC# 2012-125</org_study_id>
    <nct_id>NCT01681095</nct_id>
  </id_info>
  <brief_title>Custodiol-HTK Solution as a Cardioplegic Agent</brief_title>
  <official_title>Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc Sakwa, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essential Pharmaceuticals, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate that Custodiol-HTK is not inferior to cold
      cardioplegic solution in patients undergoing cardiovascular surgery requiring cardioplegic
      arrest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate that Custodiol is not inferior to cold
      cardioplegic solution for myocardial protection by comparing standard cold blood
      cardioplegia to Custodiol solution with respect to myocardial injury as measured by Creatine
      phosphokinase MB isoenzyme (CK-MB),troponin-I at 7 hours post surgery and changes in
      ejection fraction by trans-thoracic echocardiogram (TTE)or trans-esophageal echocardiogram
      (TEE) at 24 hours post surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Creatine phosphokinase MB isoenzyme (CK-MB)and troponin-I</measure>
    <time_frame>7 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To demonstrate that Custodiol-HTK is not inferior to cold cardioplegic solution for myocardial protection by comparing standard cold blood cardioplegia to Custodiol solution with respect to myocardial injury as measured by:
o Creatine phosphokinase MB isoenzyme (CK-MB)and troponin-I at 7 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ejection fraction by TTE</measure>
    <time_frame>at 24 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To demonstrate that Custodiol-HTK is not inferior to cold cardioplegic solution for myocardial protection by comparing standard cold blood cardioplegia to Custodiol solution with respect tomyocardial injury as measured by:
o Changes in ejection fraction by TTE at 24 hours post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac dysrhythmias</measure>
    <time_frame>up to 36 hrs post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequency of new or worsening of cardiac dysrhythmias will be compared between the two randomization arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause mortality and cardiovascular related mortality will be recorded. A Society of Thoracic Surgeons (STS) database review will be conducted post-op after 30 days to assess for cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on Mechanically Assisted Ventilation</measure>
    <time_frame>up to 36 hours post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>time of intubation, time of arrival in the cardiac critical care unit and time of extubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Markers - Creatine phosphokinase MB isoenzyme (CK-MB)and troponin</measure>
    <time_frame>24 and 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Biochemical Markers - Creatine phosphokinase MB isoenzyme(CK-MB)and troponin-I cardiac markers will be measured preoperatively, at 24 and 48 hours postoperatively1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Vasopressor / Inotropic Agent</measure>
    <time_frame>up to 36 hours post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Postoperative inotropic support greater than 20 minutes will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>ICU length of stay in total hours of an expected average of 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants will be followed for the duration of their hospital stay an expected average of 5 days. The ICU length of stay is expected to average 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood Gases</measure>
    <time_frame>up to 36 hours post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>recorded in surgery after anesthesia induction, upon arrival to ICU, after accelerated vent wean and after spontaneous breathing trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Levels</measure>
    <time_frame>24 and 48 hours post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>up to 36 hours post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Two of the following 3 criteria will need to be fulfilled to diagnose a myocardial infarction: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Q waves on EKG of more than 0.03 seconds</measure>
    <time_frame>24 and 48 hours post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 12-lead EKG will be recorded daily, upon arrival to the ICU, at 24 and 48 hours post-op. These will be compared with a pre-operative EKG for changes relating to Q waves or dysrhythmias.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Disease</condition>
  <condition>Heart Diseases</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Cardioplegia:  Custodiol HTK Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.
Custodiol-HTKcardioplegia will be delivered to establish and maintain cardiac arrest.  After cross-clamping of the aorta approximately 1-2L of Custodiol-HTK will be infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml may be administered as needed. The cardioplegic solution will be delivered at a temperature of 4°C - 10°C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold Blood Cardioplegia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood Cardioplegic Solution: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution)22, contains the following components in a 500cc bag of D5W: 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.
Cold blood cardioplegia will be administered after cross-clamping the aorta, at least 1000mL of a 4:1 mixture of cold blood: cold crystalloid will be administered at a pressure of 300mmHg or less via a twin roller pump.  Every 20 minutes an additional &gt; 200mL will be administered in an antegrade/retrograde fashion throughout the remainder of the case.  The cardioplegic solution will be delivered at a temperature of 4°C - 8°C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol HTK</intervention_name>
    <description>After cross-clamping of the aorta approximately 1-2L of Custodiol-HTK will be infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml may be administered as needed. The cardioplegic solution will be delivered at a temperature of 4°C - 10°C.</description>
    <arm_group_label>Cardioplegia:  Custodiol HTK Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cold Blood Cardioplegia</intervention_name>
    <description>After cross-clamping the aorta, at least 1000mL of a 4:1 mixture of cold blood: cold crystalloid will be administered at a pressure of 300mmHg or less via a twin roller pump.  Every 20 minutes an additional &gt; 200mL will be administered in an antegrade/retrograde fashion throughout the remainder of the case.  The cardioplegic solution will be delivered at a temperature of 4°C - 8°C.</description>
    <arm_group_label>Cold Blood Cardioplegia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing scheduled cardiac surgery requiring cardioplegic arrest with
             expected cross clamp time&gt;45 minutes

          -  Patients age 18 and older

        Exclusion Criteria:

          -  Pregnant women*

          -  Urgent or emergent cases

          -  Repeat cardiovascular surgical procedures

          -  Patients on dialysis

          -  Any known allergies to components of either cardioplegia solution *All women of child
             bearing potential must have a negative serum or urine pregnancy test.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Sakwa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Tapp, RN, BSN</last_name>
    <phone>248-551-0194</phone>
    <email>dtapp@beaumont.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Walker, RN, BSN,CCRP</last_name>
    <phone>248-551-7930</phone>
    <email>bwalker@beaumont.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Tapp, RN, BSN</last_name>
      <phone>248-551-0194</phone>
      <email>dtapp@beaumont.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brian Walker, RN, BSN</last_name>
      <phone>248-551-7930</phone>
      <email>bwalker@beaumont.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Shannon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nickolas Tepe, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phillip Robinson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Altshuler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hisamoto Kazuhiro, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Robinson, CCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Shaffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Braathen B, Jeppsson A, Scherstén H, Hagen OM, Vengen Ø, Rexius H, Lepore V, Tønnessen T. One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study. J Thorac Cardiovasc Surg. 2011 Apr;141(4):995-1001. Epub 2010 Aug 30.</citation>
    <PMID>20800244</PMID>
  </reference>
  <reference>
    <citation>Careaga G, Salazar D, Téllez S, Sánchez O, Borrayo G, Argüero R. Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res. 2001 Jul-Aug;32(4):296-9.</citation>
    <PMID>11440787</PMID>
  </reference>
  <reference>
    <citation>Hachida M, Ookado A, Nonoyama M, Koyanagi H. Effect of HTK solution for myocardial preservation. J Cardiovasc Surg (Torino). 1996 Jun;37(3):269-74.</citation>
    <PMID>8698763</PMID>
  </reference>
  <reference>
    <citation>Yang Q, He GW. Effect of cardioplegic and organ preservation solutions and their components on coronary endothelium-derived relaxing factors. Ann Thorac Surg. 2005 Aug;80(2):757-67. Review.</citation>
    <PMID>16039259</PMID>
  </reference>
  <reference>
    <citation>Beyersdorf F, Krause E, Sarai K, Sieber B, Deutschländer N, Zimmer G, Mainka L, Probst S, Zegelman M, Schneider W, et al. Clinical evaluation of hypothermic ventricular fibrillation, multi-dose blood cardioplegia, and single-dose Bretschneider cardioplegia in coronary surgery. Thorac Cardiovasc Surg. 1990 Feb;38(1):20-9.</citation>
    <PMID>2106735</PMID>
  </reference>
  <reference>
    <citation>Savini C, Camurri N, Castelli A, Dell'Amore A, Pacini D, Suarez SM, Grillone G, Di Bartolomeo R. Myocardial protection using HTK solution in minimally invasive mitral valve surgery. Heart Surg Forum. 2005;8(1):E25-7.</citation>
    <PMID>15769709</PMID>
  </reference>
  <reference>
    <citation>Braathen B, Tønnessen T. Cold blood cardioplegia reduces the increase in cardiac enzyme levels compared with cold crystalloid cardioplegia in patients undergoing aortic valve replacement for isolated aortic stenosis. J Thorac Cardiovasc Surg. 2010 Apr;139(4):874-80. Epub 2009 Jul 26.</citation>
    <PMID>19660338</PMID>
  </reference>
  <reference>
    <citation>Hendrikx M, Jiang H, Gutermann H, Toelsie J, Renard D, Briers A, Pauwels JL, Mees U. Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia. J Thorac Cardiovasc Surg. 1999 Sep;118(3):452-9.</citation>
    <PMID>10469959</PMID>
  </reference>
  <reference>
    <citation>Aarsaether E, Stenberg TA, Jakobsen Ø, Busund R. Mechanoenergetic function and troponin T release following cardioplegic arrest induced by St Thomas' and histidine-tryptophan-ketoglutarate cardioplegia--an experimental comparative study in pigs. Interact Cardiovasc Thorac Surg. 2009 Oct;9(4):635-9. Epub 2009 Jul 23.</citation>
    <PMID>19628529</PMID>
  </reference>
  <reference>
    <citation>Gallandat Huet RC, Karliczek GF, van der Heide JN, Brenken U, Mooi B, van der Broeke JJ, Jenkins I, de Geus AF. Clinical effect of Bretschneider-HTK and St. Thomas cardioplegia on hemodynamic performance after bypass measured using an automatic datalogging database system. Thorac Cardiovasc Surg. 1988 Jun;36(3):151-6.</citation>
    <PMID>3145585</PMID>
  </reference>
  <reference>
    <citation>Arslan A, Sezgin A, Gultekin B, Ozkan S, Akay T, Uguz E, Tasdelen A, Aslamaci S. Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection. Transplant Proc. 2005 Sep;37(7):3219-22.</citation>
    <PMID>16213352</PMID>
  </reference>
  <reference>
    <citation>Fannelop T, Dahle GO, Salminen PR, Moen CA, Matre K, Mongstad A, Eliassen F, Segadal L, Grong K. Multidose cold oxygenated blood is superior to a single dose of Bretschneider HTK-cardioplegia in the pig. Ann Thorac Surg. 2009 Apr;87(4):1205-13.</citation>
    <PMID>19324152</PMID>
  </reference>
  <reference>
    <citation>Schaper J, Scheld HH, Schmidt U, Hehrlein F. Ultrastructural study comparing the efficacy of five different methods of intraoperative myocardial protection in the human heart. J Thorac Cardiovasc Surg. 1986 Jul;92(1):47-55.</citation>
    <PMID>3088335</PMID>
  </reference>
  <reference>
    <citation>Bical OM, Fromes Y, Paumier D, Gaillard D, Foiret JC, Trivin F. Does warm antegrade intermittent blood cardioplegia really protect the heart during coronary surgery? Cardiovasc Surg. 2001 Apr;9(2):188-93.</citation>
    <PMID>11250190</PMID>
  </reference>
  <reference>
    <citation>Allen BS, Winkelmann JW, Hanafy H, Hartz RS, Bolling KS, Ham J, Feinstein S. Retrograde cardioplegia does not adequately perfuse the right ventricle. J Thorac Cardiovasc Surg. 1995 Jun;109(6):1116-24; discussion 1124-6.</citation>
    <PMID>7776676</PMID>
  </reference>
  <reference>
    <citation>Sakata J, Morishita K, Ito T, Koshino T, Kazui T, Abe T. Comparison of clinical outcome between histidine-triptophan-ketoglutalate solution and cold blood cardioplegic solution in mitral valve replacement. J Card Surg. 1998 Jan;13(1):43-7.</citation>
    <PMID>9892485</PMID>
  </reference>
  <reference>
    <citation>Asano H, Kyo S, Ogiwara M, Tsunemoto M, Yokote Y, Omoto R, Koike K, Kobayashi T, Kobayashi J, Taketazu M. [Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery]. Kyobu Geka. 1999 Jan;52(1):82-6. Japanese.</citation>
    <PMID>10024809</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>August 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Marc Sakwa, MD</investigator_full_name>
    <investigator_title>Principal  Investigator</investigator_title>
  </responsible_party>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Mannitol</keyword>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Cardiovascular agents</keyword>
  <keyword>Cardioplegic Solutions</keyword>
  <keyword>HTK solution</keyword>
  <keyword>Myocardial protection</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Heart Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardioplegic Solutions</mesh_term>
    <mesh_term>Cardiovascular Agents</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Procaine</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
